The results uncovered that miRNAs could make HER2+ breast cancer cells more susceptible to targeted therapy and have the potential to improve existing therapies for HER2+ breast cancer by combining targeted drugs with miRNAs [186]. Here, ERBB2 is linked to breast carcinoma.